Arcus Biosciences

Creating Innovative Cancer Immunotherapies

Learn more about us

Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.

Learn more

Press Releases

June 12, 2018 in Press Releases

Arcus Biosciences Announces the Promotion of Jennifer Jarrett to Chief Operating Officer

Read More
June 11, 2018 in Press Releases

Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations

Read More
May 29, 2018 in Press Releases

Arcus Biosciences Announces Participation at Upcoming Investor Conference

Read More

Pipeline

AB928

AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.

AB154

AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.

AB122

AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.

AB680

AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.

Go to Pipeline

Arcus has approximately 75 employees with significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership